[New and emerging treatments for multiple sclerosis].

Area of Science:

• Neuroimmunology
• Pharmacology

Context:

• Recent approvals of novel disease-modifying therapies (DMTs) for multiple sclerosis (MS).
• Comparison of new DMTs against older, first-line treatments, highlighting improved efficacy and convenience (e.g., oral agents).
• Acknowledgement of the potential for severe side effects associated with advanced MS treatments.

Purpose:

• To review the evolving landscape of multiple sclerosis treatment algorithms.
• To emphasize the critical need to balance treatment efficacy with long-term safety profiles.
• To highlight the role of fundamental pathophysiology in developing next-generation MS therapeutics.

Summary:

• Newly approved disease-modifying therapies for MS demonstrate superior effectiveness in preventing relapses and CNS lesions compared to traditional treatments.
• These advanced therapies, including oral medications, offer enhanced convenience but necessitate careful monitoring due to potentially severe adverse effects.
• The continuous evolution of MS treatment strategies is informed by long-term safety data and a deeper understanding of disease mechanisms.

Impact:

• Informs clinical decision-making regarding the selection and management of multiple sclerosis therapies.
• Drives further research into the immunological and repair pathways of multiple sclerosis.
• Facilitates the development of innovative treatments targeting specific disease mechanisms for improved patient outcomes.